Aarti Pharmalabs Limited · NSE: AARTIPHARM · BSE: 543748

Aarti Pharmalabs

Quarterly results as filed with BSE. Latest: Q1 FY27 (Apr–Jun 2026), filed 07 Aug 2026.

Q1 FY27 · Consolidated

Revenue
535.80₹ Cr
+38.7% vs year ago
Net profit
76.14₹ Cr
+53.8% vs year ago
EPS, basic
8.40₹
+53.8% vs year ago
Net margin
14.2%
+1.4 pts vs year ago
Revenue₹ crore · consolidated · last 12 quarters
Q2 FY24: ₹439.80 CrQ3 FY24: ₹448.69 CrQ4 FY24: ₹505.77 CrQ1 FY25: ₹555.49 CrQ2 FY25: ₹458.03 CrQ3 FY25: ₹537.78 CrQ4 FY25: ₹563.78 CrQ1 FY26: ₹386.19 CrQ2 FY26: ₹418.33 CrQ3 FY26: ₹432.27 CrQ4 FY26: ₹582.64 CrQ1 FY27: ₹535.80 CrQ3 ’24Q1 ’25Q3 ’25Q1 ’26Q3 ’26Q1 ’27
Net profit₹ crore · consolidated · last 12 quarters
Q2 FY24: ₹51.80 CrQ3 FY24: ₹52.76 CrQ4 FY24: ₹65.25 CrQ1 FY25: ₹55.45 CrQ2 FY25: ₹54.62 CrQ3 FY25: ₹73.99 CrQ4 FY25: ₹88.34 CrQ1 FY26: ₹49.50 CrQ2 FY26: ₹27.92 CrQ3 FY26: ₹47.96 CrQ4 FY26: ₹61.12 CrQ1 FY27: ₹76.14 CrQ3 ’24Q1 ’25Q3 ’25Q1 ’26Q3 ’26Q1 ’27

Quarter by quarter

Consolidated · ₹ crore
QuarterRevenueYoYNet profitYoYEPS (₹)Filed
Q1 FY27Apr–Jun 2026535.80+38.7%76.14+53.8%8.4007 Aug 2026
Q4 FY26Jan–Mar 2026582.64+3.3%61.12−30.8%6.7425 May 2026
Q3 FY26Oct–Dec 2025432.27−19.6%47.96−35.2%5.2909 Feb 2026
Q2 FY26Jul–Sep 2025418.33−8.7%27.92−48.9%3.0811 Nov 2025
Q1 FY26Apr–Jun 2025386.19−30.5%49.50−10.7%5.4619 Sep 2025
Q4 FY25Jan–Mar 2025563.78+11.5%88.34+35.4%9.7510 May 2025
Q3 FY25Oct–Dec 2024537.78+19.9%73.99+40.2%8.1606 Feb 2025
Q2 FY25Jul–Sep 2024458.03+4.1%54.62+5.4%6.0329 Oct 2024
Q1 FY25Apr–Jun 2024555.49+21.2%55.45+17.8%6.1206 Aug 2024
Q4 FY24Jan–Mar 2024505.77+4.3%65.25+52.2%7.2015 May 2024
Q3 FY24Oct–Dec 2023448.69—52.76—5.8208 Feb 2024
Q2 FY24Jul–Sep 2023439.80—51.80—5.7221 Nov 2023
Q1 FY24Apr–Jun 2023458.36—47.09—5.2005 Aug 2023
Q4 FY23Jan–Mar 2023485.06—42.87—4.7318 May 2023
Standalone results
Standalone · ₹ crore
QuarterRevenueYoYNet profitYoYEPS (₹)Filed
Q1 FY27Apr–Jun 2026534.59+42.4%71.31+39.2%7.8707 Aug 2026
Q4 FY26Jan–Mar 2026579.70+9.5%62.03−30.2%6.8425 May 2026
Q3 FY26Oct–Dec 2025425.25−9.7%43.84−40.4%4.8409 Feb 2026
Q2 FY26Jul–Sep 2025417.29+10.6%30.93−35.3%3.4111 Nov 2025
Q1 FY26Apr–Jun 2025375.31−4.6%51.22+8.6%5.6519 Sep 2025
Q4 FY25Jan–Mar 2025529.62+27.7%88.85+41.0%9.8010 May 2025
Q3 FY25Oct–Dec 2024470.95+26.3%73.52+52.6%8.1106 Feb 2025
Q2 FY25Jul–Sep 2024377.29+5.9%47.84+16.2%5.2829 Oct 2024
Q1 FY25Apr–Jun 2024393.49+9.9%47.14−1.0%5.2006 Aug 2024
Q4 FY24Jan–Mar 2024414.82+10.8%63.02+57.6%6.9515 May 2024
Q3 FY24Oct–Dec 2023373.03—48.19—5.3208 Feb 2024
Q2 FY24Jul–Sep 2023356.14—41.18—4.6121 Nov 2023
Q1 FY24Apr–Jun 2023358.14—47.63—5.2605 Aug 2023
Q4 FY23Jan–Mar 2023374.27—39.99—4.4118 May 2023

28 filings on record for this company.